Skip to main content

Table 4 Percent change in total cholesterol, HDL-C, and triglyceride from baseline at week 8

From: A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy

Variable

Treatment groups

FMS/ALD + RSV

vs. FMS/ALD

FMS/ALD + RSV

vs. FMS + RSV

FMS/ALD + RSVa

(n = 43)

FMS/ALDb

(n = 45)

FMS + RSVc

(n = 43)

LSM difference (SE)

P-valued

LSM difference (SE)

P-valued

TC (mg/dL)

 Baseline

221.77 ± 28.38

213.51 ± 35.56

223.77 ± 40.14

    

 Week 8

150.81 ± 33.64

205.91 ± 39.13

144.37 ± 29.51

    

 Percent change

–31.73 ± 13.93

–3.18 ± 12.76

–34.44 ± 13.35

    

 P-value

 < 0.001

0.102

 < 0.001

    

ANCOVA result

 LSM (SE)

–31.44 ± 2.03

–3.45 ± 1.98

–34.32 ± 1.99

–27.99 ± 2.85

 < 0.001

2.46 ± 2.81

0.384

HDL-C (mg/dL)

 Baseline

48.44 ± 13.65

45.93 ± 12.07

48.84 ± 10.59

    

 Week 8

55.00 ± 16.16

46.53 ± 11.01

53.42 ± 10.41

    

 Percent change

14.60 ± 18.50

3.32 ± 17.51

11.51 ± 18.84

    

 P-value

 < 0.001

0.211

0.002

    

ANCOVA result

 LSM (SE)

15.18 ± 2.62

2.77 ± 2.56

11.62 ± 2.68

12.41 ± 3.68

0.001

2.88 ± 3.80

0.450

TG (mg/dL)

 Baseline

196.42 ± 79.24

180.53 ± 63.86

188.40 ± 75.13

    

 Week 8

161.74 ± 88.30

181.09 ± 77.77

148.14 ± 70.34

    

 Percent change

–14.84 ± 35.59

7.73 ± 46.90

–15.73 ± 38.11

    

 P-value

0.009

0.629

0.001

    

ANCOVA result

 LSM (SE)

–13.30 ± 6.07

6.26 ± 5.94

–16.29 ± 5.42

–19.56 ± 8.52

0.024

2.00 ± 7.67

0.795

  1. Data are presented as mean ± standard deviation unless otherwise indicated
  2. TC Total cholesterol, HDL-C High-density lipoprotein cholesterol, TG Triglyceride, ANCOVA Analysis of covariance, LSM Least square mean, SE Standard error
  3. a FMS/ALD + RSV; study group, fimasartan 60 mg/amlodipine 10 mg + rosuvastatin 20 mg treatment
  4. b FMS/ALD; control 1 group, fimasartan 60 mg/amlodipine 10 mg treatment
  5. c FMS + RSV; control 2 group, fimasartan 60 mg + rosuvastatin 20 mg treatment
  6. d Comparison between treatment was analyzed by ANCOVA model adjusted for factor and baseline values
Back to article page

Clinical Hypertension

ISSN: 2056-5909

Contact us